Cullinan Therapeutics, Inc.

Industry

  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Gene Therapy, Cell Therapy

Other Names/Subsidiaries

  • Cullinan Florentine
  • Cullinan Management, Inc.
  • Cullinan MICA
  • Cullinan Pearl
  • Cullinan Oncology, Inc.
  • Cullinan Apollo
  • Florentine
  • Jade
  • NexGem
  • Opal
  • Topaz
See more in Biomedtracker

Latest on Cullinan Therapeutics, Inc.

Scrip

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Xu Hu

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. SunRock, Escugen Partner To Develo

Scrip

Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

 
• By Eleanor Malone

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Scrip

Cullinan/Taiho’s Zipalertinib Stands To Benefit From A Clear Market

 
• By Alaric DeArment

Cullinan Therapeutics and Taiho have a significant market opportunity with zipalertinib after successful results in the Phase I/II REZILIENT1 trial among previously treated non-small cell lung cancer

Scrip

Finance Watch: Bain Capital Raises $3bn For Fourth Life Sciences Fund

 
• By Mandy Jackson

Bain Capital Life Sciences (BCLS) raised its largest investment fund yet, nearly doubling the amount of money it has at its disposal to back both private and public drug developers, medical device and